2025
Underrepresentation and exclusion of patients with cardiovascular disease in intensive care randomized controlled trials
Ali T, Grimshaw A, Thomas A, Solomon M, Ross J, Miller P. Underrepresentation and exclusion of patients with cardiovascular disease in intensive care randomized controlled trials. European Heart Journal Acute Cardiovascular Care 2025, 14: 259-267. PMID: 39950988, PMCID: PMC12082296, DOI: 10.1093/ehjacc/zuaf023.Peer-Reviewed Original ResearchContemporary cardiac intensive care unitsRandomized Controlled TrialsIschemic heart diseaseCardiovascular diseaseHeart failureDisciplines of critical care medicineHistory of heart failureProspective randomized controlled trialsHeart diseaseControlled TrialsExclusion criteriaMultivariate logistic regression analysisCardiac intensive care unitProportion of patientsExclusion of patientsComorbid cardiovascular diseaseCardiovascular disease historyIntensive care unitLogistic regression analysisApplication of randomized controlled trialsComplex patient populationGeneral internal medicineCardiovascular disease comorbiditiesMulticenter trialIndependent predictors
2024
Treating Migraine Patients With Cardiovascular Risks
Wang K, Sico J. Treating Migraine Patients With Cardiovascular Risks. Neurology 2024, 103: e210196. PMID: 39621947, DOI: 10.1212/wnl.0000000000210196.Peer-Reviewed Original ResearchNonaspirin nonsteroidal anti-inflammatory drugsCardiovascular safety profileSafety profileCardiovascular eventsCardiovascular riskIncreased riskIncreased risk of ischemic eventsRisk of ischemic eventsNonsteroidal anti-inflammatory drugsExclusion of patientsAdverse cardiovascular eventsMyocardial infractionRisk of acute cardiovascular eventsEffective acute treatmentTreat migraine patientsRisk of myocardial infractionCOX-2 inhibitorsAnti-inflammatory drugsAcute cardiovascular eventsMigraine patientsAcute treatmentIschemic eventsManaging cardiovascular riskRandomized trialsCOX-2Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses — IVY Network, September 1, 2022–March 30, 2023
Lewis N, Harker E, Leis A, Zhu Y, Talbot H, Grijalva C, Halasa N, Chappell J, Johnson C, Rice T, Casey J, Lauring A, Gaglani M, Ghamande S, Columbus C, Steingrub J, Shapiro N, Duggal A, Felzer J, Prekker M, Peltan I, Brown S, Hager D, Gong M, Mohamed A, Exline M, Khan A, Wilson J, Mosier J, Qadir N, Chang S, Ginde A, Mohr N, Mallow C, Harris E, Johnson N, Srinivasan V, Gibbs K, Kwon J, Vaughn I, Ramesh M, Safdar B, DeCuir J, Surie D, Dawood F, Ellington S, Self W, Martin E. Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses — IVY Network, September 1, 2022–March 30, 2023. Vaccine 2024, 43: 126492. PMID: 39515195, DOI: 10.1016/j.vaccine.2024.126492.Peer-Reviewed Original ResearchCo-circulating virusesRespiratory syncytial virusCOVID-19-associated hospitalizationVaccine effectivenessControl groupRespiratory pathogensInfluenza-associated hospitalizationsExclusion of patientsStudies of vaccine effectivenessAcute respiratory illnessTest-negative studySentinel Surveillance NetworkEstimates of VEInfluenza VEInfluenza-associatedVE controlsReal-world analysisSyncytial virusVE estimatesOverall VEVE analysisPatientsInfluenzaRespiratory illnessVaccine-preventableFirst episode psychoses in people over-35 years old: uncovering potential actionable targets for early intervention services
Ferrara M, Domenicano I, Marchi A, Zaffarami G, Onofrio A, Benini L, Sorio C, Gentili E, Murri M, Toffanin T, Little J, Grassi L. First episode psychoses in people over-35 years old: uncovering potential actionable targets for early intervention services. Psychiatry Research 2024, 339: 116034. PMID: 38906051, DOI: 10.1016/j.psychres.2024.116034.Peer-Reviewed Original ResearchLong-Acting Injectable AntipsychoticsFirst-episode psychosisEarly intervention servicesPrescribing long-acting injectable antipsychoticsNon-affective first-episode psychosisIntervention servicesCommunity psychiatric servicesInjectable antipsychoticsPsychotic onsetEpisode psychosisAffective psychosisPsychiatric servicesPsychosisExclusion of patientsAccess treatmentClinical characteristicsRetrospective studyOlder patientsPatientsAntipsychoticsAntidepressantsAge groupsWomenGroupIndividualsNavigating the Complexities of Brain Metastases Management.
Amouzegar A, Haig S, Kahn A, Tawbi H, Jones J, Goldberg S. Navigating the Complexities of Brain Metastases Management. American Society Of Clinical Oncology Educational Book 2024, 44: e433694. PMID: 38781565, DOI: 10.1200/edbk_433694.Peer-Reviewed Original ResearchConceptsBrain metastasesSystemic therapySolid tumorsIncidence of brain metastasesManagement of brain metastasesEfficacy of systemic therapyBrain metastasis managementMetastatic solid tumorsComplication of advanced cancerExclusion of patientsEnhanced imaging technologiesMetastasis managementSystemic treatmentTargeted therapyBreast cancerExtended survivalClinical dataClinical trialsMetastasisAdvanced cancerTherapyEarly detectionTumorPatientsCancer
2023
Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy
Castro D, Prajapati S, Feng M, Chan E, Lee K, Paul T, Sehgal I, Patel J, Li X, Zengin Z, Ebrahimi H, Govindarajan A, Meza L, Mercier B, Chawla N, Dizman N, Philip E, Hsu J, Bergerot C, Chehrazi‐Raffle A, Rock A, Liu S, Tripathi A, Dorff T, Pal S. Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy. BJU International 2023, 133: 297-304. PMID: 37548533, DOI: 10.1111/bju.16148.Peer-Reviewed Original ResearchHBV/HCV infectionExclusion of patientsHepatitis B virusConcurrent malignancyBrain metastasesEligibility criteriaHCV infectionSystemic therapyRCC trialsVirus infectionExact testHepatitis C virus infectionHuman immunodeficiency virus (HIV) infectionC virus infectionImmunodeficiency virus infectionFisher's exact testRestrictive eligibility criteriaContext of HIVChi-square testPrevalent comorbiditiesHIV infectionImmunotherapy trialsPatient populationB virusTrial characteristicsRheumatoid arthritis patients are at increased risk for adverse events following lumbar discectomy
Ratnasamy P, Rudisill K, Gouzoulis M, Kammien A, Grauer J. Rheumatoid arthritis patients are at increased risk for adverse events following lumbar discectomy. The Spine Journal 2023, 23: 990-996. PMID: 36990283, DOI: 10.1016/j.spinee.2023.03.012.Peer-Reviewed Original ResearchConceptsLumbar discectomy patientsAdverse eventsRheumatoid arthritisLumbar discectomyPatient ageDiscectomy patientsMinor adverse eventsRetrospective cohort studyLumbar spinal surgeryPatient's medication regimenElixhauser Comorbidity IndexExclusion of patientsRA medicationsComorbidity indexCohort studyMedication regimenPrior diagnosisPredictive factorsAdverse outcomesSubgroup analysisSpinal surgeryInfection diagnosisAutoinflammatory diseasesHigher oddsDiscectomy
2022
Racial/Ethnic Variation in White Matter Hyperintensity Progression in the ACCORDION MIND Study
Herman AL, de Havenon A, Falcone GJ, Prabhakaran S, Sheth KN. Racial/Ethnic Variation in White Matter Hyperintensity Progression in the ACCORDION MIND Study. The Neurologist 2022, 28: 157-159. PMID: 35834785, DOI: 10.1097/nrl.0000000000000454.Peer-Reviewed Original ResearchConceptsWMH progressionWhite matter hyperintensitiesLow-density lipoproteinCardiovascular riskWhite patientsBlack patientsWMH volumeSystolic blood pressure levelsWhite matter hyperintensity progressionBlack diabetic patientsBlood pressure levelsExclusion of patientsMagnetic resonance imagingDiabetes (ACCORD) trialDiabetic patientsMean SBPPrimary outcomePatient raceMultivariate regression modelMatter hyperintensitiesA1c measurementHigh riskPatientsNormal rangeCognitive decline
2020
Anti-modified citrullinated vimentin antibody: a novel biomarker associated with cardiac systolic dysfunction in patients with rheumatoid arthritis
Norouzi S, Javinani A, Aminorroaya A, Masoumi M. Anti-modified citrullinated vimentin antibody: a novel biomarker associated with cardiac systolic dysfunction in patients with rheumatoid arthritis. BMC Cardiovascular Disorders 2020, 20: 390. PMID: 32847506, PMCID: PMC7448352, DOI: 10.1186/s12872-020-01676-x.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionCardiac systolic dysfunctionCardiovascular diseaseSystolic dysfunctionRheumatoid arthritisReduced left ventricular ejection fractionPredictors of left ventricular ejection fractionAnti-modified citrullinated vimentinEchocardiographic parameters of systolicDisease Activity Score-28Anti-MCV levelsParameters of systolicAssociation of autoantibodiesVentricular ejection fractionConcomitant cardiovascular diseaseExclusion of patientsSusceptibility to cardiovascular diseaseReceiver operating characteristic curveDuration of diseaseCardiovascular disease risk factorsAnti-citrullinated proteinFramingham risk scoreCross-sectional studyTransthoracic echocardiographyDiastolic dysfunction
2019
Early Prognostication of 1-Year Outcome After Subarachnoid Hemorrhage: The FRESH Score Validation
Witsch J, Kuohn L, Hebert R, Cord B, Sansing L, Gilmore EJ, Hwang DY, Petersen N, Falcone GJ, Matouk C, Sheth KN. Early Prognostication of 1-Year Outcome After Subarachnoid Hemorrhage: The FRESH Score Validation. Journal Of Stroke And Cerebrovascular Diseases 2019, 28: 104280. PMID: 31326270, DOI: 10.1016/j.jstrokecerebrovasdis.2019.06.038.Peer-Reviewed Original ResearchConceptsSpontaneous subarachnoid hemorrhageModified Rankin ScaleLong-term outcomesSubarachnoid hemorrhageUnfavorable outcomePercent of patientsExclusion of patientsStratification of patientsScore variablesAneurysmal etiologyBleeding sourceRankin ScaleFunctional outcomeMean ageEarly prognosticationPrognostication scoresStudy investigatorsHospital resourcesPatientsDisability partAneurysm coilingOutcomesHigh gradeCharacteristic curveHemorrhageEffect of β-blockers on triggering of symptomatic atrial fibrillation by anger or stress
Lampert R, Burg MM, Jamner LD, Dziura J, Brandt C, Li F, Donovan T, Soufer R. Effect of β-blockers on triggering of symptomatic atrial fibrillation by anger or stress. Heart Rhythm 2019, 16: 1167-1173. PMID: 31171436, PMCID: PMC6759206, DOI: 10.1016/j.hrthm.2019.03.004.Peer-Reviewed Original ResearchConceptsAtrial fibrillationΒ-blockersAF episodesHistory of AFControl periodSymptomatic AF episodesSymptomatic atrial fibrillationΒ-blocker useExclusion of patientsPersistent atrial fibrillationHolter monitoringAF symptomsPatientsPatient exposureCase periodFibrillationMood statesEpisodesEvent monitorDeleterious physiological responsesExposurePhysiological responsesDiary dataSotalol
2017
Postprandial Dosing of Bolus Insulin in Patients with type 1 Diabetes: a Cross-sectional Study Using Data From the T1d Exchange Registry
Peters A, Van Name MA, Thorsted B, Piltoft JS, Tamborlane WV. Postprandial Dosing of Bolus Insulin in Patients with type 1 Diabetes: a Cross-sectional Study Using Data From the T1d Exchange Registry. Endocrine Practice 2017, 23: 1201-1209. PMID: 28704103, DOI: 10.4158/ep171813.or.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBlood GlucoseBlood Glucose Self-MonitoringChildChild, PreschoolCross-Sectional StudiesDiabetes Mellitus, Type 1Diabetic KetoacidosisDrug Dosage CalculationsFemaleHumansHypoglycemiaInfantInsulinInsulin Infusion SystemsMaleMiddle AgedPostprandial PeriodRegistriesYoung AdultConceptsRapid-acting insulin analoguesLarger insulin doseT1D Exchange RegistryType 1 diabetesCross-sectional studyDiabetic ketoacidosisInsulin doseGreater prevalenceCurrent rapid-acting insulin analoguesInsulin analoguesSelf-monitoring blood glucosePercent of patientsCharacteristics of patientsPoor glycemic controlExclusion of patientsBody mass indexContinuous glucose monitoringPostprandial dosingGlycemic controlSevere hypoglycemiaBolus insulinMass indexEnrollment questionnaireBlood glucoseGlucose levels
2015
Poor visualization limits diagnosis of proximal junctional kyphosis in adolescent idiopathic scoliosis
Basques BA, Long WD, Golinvaux NS, Bohl DD, Samuel AM, Lukasiewicz AM, Webb ML, Grauer JN. Poor visualization limits diagnosis of proximal junctional kyphosis in adolescent idiopathic scoliosis. The Spine Journal 2015, 17: 784-789. PMID: 26523958, DOI: 10.1016/j.spinee.2015.10.040.Peer-Reviewed Original ResearchConceptsProximal junctional kyphosisProximal junctional angleAdolescent idiopathic scoliosisUpper instrumented vertebraIntra-class correlation coefficientJunctional kyphosisInter-rater reliabilityIdiopathic scoliosisRetrospective cohort studyPosterior instrumented fusionExclusion of patientsSagittal Cobb anglePosterior spinal fusionIntra-rater reliabilityCohort studyInstrumented fusionAIS patientsSingle institutionPostoperative filmsSpinal fusionCobb angleUpright filmsPoor visualizationPatientsDiagnosisSafety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial
Sagara I, Beavogui A, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, Camara D, Somé A, Coulibaly A, Traore O, Dara N, Kabore M, Thera I, Compaore Y, Sylla M, Nikiema F, Diallo M, Dicko A, Gil J, Borrmann S, Duparc S, Miller R, Doumbo O, Shin J, Bjorkman A, Ouedraogo J, Sirima S, Djimdé A. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. The Lancet Infectious Diseases 2015, 16: 189-198. PMID: 26601738, PMCID: PMC4726763, DOI: 10.1016/s1473-3099(15)00318-7.Peer-Reviewed Original ResearchConceptsSubstudy analysisFirst episodeFirst treatmentArtemisinin-based combination treatmentDeveloping Countries Clinical Trials PartnershipPrimary safety endpointPyronaridine-artesunate efficacyHistory of feverIncidence of hepatotoxicityAdverse event frequencyExclusion of patientsUK Medical Research CouncilMedical Research CouncilParasitological responseSafety endpointArtemether-lumefantrineMalaria episodesTreat analysisAfrican patientsMalaria treatmentClinical trialsMalaria VentureLaboratory valuesAlanine aminotransferaseHealth facilities
2005
Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
Chung K, Shia J, Kemeny N, Shah M, Schwartz G, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra D, Fridman D, Kelsen D, Saltz L. Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry. Journal Of Clinical Oncology 2005, 23: 1803-1810. PMID: 15677699, DOI: 10.1200/jco.2005.08.037.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorCetuximab-based therapyColorectal cancer patientsEGFR-negative tumorsGrowth factor receptorCancer patientsNonstudy settingsEGFR negativityEpidermal growth factor receptor immunohistochemistryFactor receptorEpidermal growth factor receptor analysisMemorial Sloan-Kettering Cancer CenterIrinotecan-based regimenRefractory colorectal cancerComputed tomography scanExclusion of patientsChemotherapy-refractoryCetuximab therapyCetuximab monotherapyEvidence of activityWHO criteriaPathology reportsTomography scanCetuximabColorectal cancer
2002
Spectrum of heart failure in older patients: Results from the national heart failure project
Havranek EP, Masoudi FA, Westfall KA, Wolfe P, Ordin DL, Krumholz HM. Spectrum of heart failure in older patients: Results from the national heart failure project. American Heart Journal 2002, 143: 412-417. PMID: 11868045, DOI: 10.1067/mhj.2002.120773.Peer-Reviewed Original ResearchConceptsLong-term care facilitiesHeart failureCare facilitiesElderly patientsClinical trialsNational Heart Failure ProjectLeft ventricular ejection fractionLeft ventricular systolic functionChronic obstructive pulmonary diseaseAssociated laboratory abnormalitiesHeart Failure ProjectHistory of hypertensionPoor renal functionThird of patientsVentricular systolic functionMajority of patientsMultiple comorbid conditionsObstructive pulmonary diseaseVentricular ejection fractionExclusion of patientsLong-term hemodialysisCoronary heart diseasePopulation-based studyAcute care facilitiesEvidence-based guidance
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply